Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents

被引:0
|
作者
Luo, Y
Rockow-Magnone, SK
Joseph, MK
Bradner, J
Butler, CC
Tahir, SK
Han, EKH
Ng, SC
Severin, JM
Gubbins, EJ
Reilly, RM
Rueter, A
Simmer, RL
Holzman, TF
Giranda, VL
机构
[1] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 47S AP9A, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 4N6 AP9, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Adv Technol Pharmaceut Prod Div, Dept 4MD AP10, Abbott Pk, IL 60064 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词
G2; abrogation; Chkl; UCN01; staurosporine; chemotherapy sensitization;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Chkl is a checkpoint gene that is activated after DNA damage, It phosphorylates and inactivates Cdc25C at the late G2 phase. The inactivation of Cdc25C and consequently, the inactivation of Cdc2, are required for the G2 arrest induced by DNA damage. Methods: We treated 184B5 cell line and its E6 transformed cell lines with adriamycin in the presence of staurosporine or UCNO1 and examined induced a p53 and p21 response as well as a G1 arrest in 184B5 cells, but not in its E6 transformed cells. Staurosporine or UCNO1 abrogated the G2 arrest induced by adriamycin in both cell lines. In addition staurosporine or UCNO1 specifically sensitized p52 incompetent cells to adriamycin. Conclusion: G2/M checkpoint abrogators can potentially enhance the cytotoxic effect of conventional chemotherapeutic reagents specifically to tumor cells.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 50 条
  • [41] p53 Configures the G2/M arrest response of nucleostemin-deficient cells
    Huang, G.
    Meng, L.
    Tsai, R. Y. L.
    CELL DEATH DISCOVERY, 2015, 1
  • [42] p53 Configures the G2/M arrest response of nucleostemin-deficient cells
    G Huang
    L Meng
    RYL Tsai
    Cell Death Discovery, 1
  • [43] C-terminus of p53 is required for G2 arrest
    Nakamura, S
    Gomyo, Y
    Roth, JA
    Mukhopadhyay, T
    ONCOGENE, 2002, 21 (13) : 2102 - 2107
  • [44] C-terminus of p53 is required for G2 arrest
    Seiichi Nakamura
    Yoshihito Gomyo
    Jack A Roth
    Tapas Mukhopadhyay
    Oncogene, 2002, 21 : 2102 - 2107
  • [45] Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor
    Jain, Chetan Kumar
    Roychoudhury, Susanta
    Majumder, Hemanta Kumar
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2015, 1853 (05): : 1195 - 1204
  • [46] G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value
    Cho, NH
    Lim, SY
    Kim, YT
    Kim, D
    Kim, YS
    Kim, JW
    GYNECOLOGIC ONCOLOGY, 2003, 90 (01) : 15 - 22
  • [47] NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint
    Dellinger, RW
    Karjian, PL
    Neuteboom, STC
    ANTI-CANCER DRUGS, 2003, 14 (06) : 449 - 455
  • [48] Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells
    Eek Mariampillai, Adrian
    Hauge, Sissel
    oynebraten, Inger
    Rodland, Gro Elise
    Corthay, Alexandre
    Syljuasen, Randi G.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation
    Suganuma, M
    Kawabe, T
    Hori, H
    Funabiki, T
    Okamoto, T
    CANCER RESEARCH, 1999, 59 (23) : 5887 - 5891